Protalix BioTherapeutics, Inc. Income Statement
PLX|14 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
Protalix BioTherapeutics, Inc. reported $65M in revenue and $8M in net income for FY2025. Revenue has grown at a 44.2% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $4.4M | $3.5M | $0 | $34.9M | $8.4M | $6.6M | $388.0K |
| Cost of Revenue | $23.0M | $19.6M | $16.3M | $10.9M | $10.9M | $9.3M | $15.2M | $730.0K | $630.0K | $0 | $8.1M | $1.5M | $4.4M | $3.6M |
| Gross Profit | - | - | - | - | - | - | - | $3.6M | $2.9M | $0 | $26.3M | $1.4M | $6.9M | -$3.2M |
| SG&A Expense | $15.0M | $11.7M | $12.7M | $11.1M | $9.9M | $10.9M | $11.5M | $7.3M | $9.2M | $8.1M | $9.8M | $6.9M | $6.9M | $7.1M |
| R&D Expense | $17.1M | $29.3M | $29.7M | $38.2M | $44.6M | $33.3M | $32.2M | $24.9M | $27.4M | $29.2M | $36.7M | $37.8M | $37.7M | $27.4M |
| Operating Income | $10.5M | -$13.0M | -$20.5M | $2.7M | -$10.7M | -$19.3M | -$34.5M | -$23.7M | -$28.6M | -$34.1M | -$12.2M | -$36.5M | -$30.0M | -$32.0M |
| Interest Expense | - | - | - | - | - | - | - | - | - | $1.0M | $1.0M | $1.0M | - | - |
| Income Tax | $254.0K | $530.0K | $530.0K | $530.0K | - | - | - | - | - | - | - | - | - | - |
| Net Income | $8.3M | -$14.9M | -$27.6M | -$6.5M | -$18.3M | -$26.5M | -$83.4M | $58.0M | -$29.9M | -$27.8M | -$11.6M | -$36.5M | -$29.0M | -$31.4M |
| EPS (Basic) | $0.12 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | - | - | - | - | - | - | - | - | - |
| EPS (Diluted) | $0.09 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | -$1.80 | -$6.37 | $0.61 | -$0.32 | -$0.30 | -$0.13 | -$0.43 | -$0.36 | $0.41 |
| Shares Outstanding | 75.9M | 73.0M | 53.8M | 45.6M | 34.8M | 14.8M | 14.8M | 124.1M | 99.8M | 93.6M | 93.6M | 93.5M | 85.6M | 81.2M |
| Gross Margin | - | - | - | - | - | - | - | 83.3% | 82.1% | - | 75.4% | 17.2% | 103.3% | -821.4% |
| Operating Margin | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -542.4% | -810.6% | - | -34.9% | -435.6% | -451.2% | -8239.4% |
| Profit Margin | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | 1329.9% | -849.9% | - | -33.3% | -435.6% | -436.6% | -8103.1% |